Physician-led | Physiologist-led | P-Value | |
---|---|---|---|
Demographics | |||
N | 5321 | 5976 | |
Male | 56.6% | 60.1% | <0.01 |
Age (median) | 66 | 66 | NS |
Sinus rhythm | 91.4% | 86.4% | <0.01 |
Prognostic risk post-MPS high‡ | 9.2% | 11.7% | <0.01 |
Prognostic risk post-MPS low‡ | 73.0% | 68.8% | <0.01 |
Stress mechanism | |||
Physical (treadmill/bicycle) | 72.1% | 56.1% | <0.01 |
Pharmacological (all) | 27.9% | 43.9% | <0.01 |
Dobutamine | 10.6% | 1.1% | <0.01 |
Dipyridamole | 83.9% | 29.8% | <0.01 |
Adenosine | 5.4% | 4.2% | <0.01 |
Regadenoson | 0.2% | 64.9% | <0.01 |
‡ prognostic risk calculated post-MPS - high: >3% estimated annualised risk of major adverse cardiovascular event, low: <1%